AusperBio Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AusperBio Therapeutics Inc. - overview
Established
2019
Location
Foster City, CA, US
Primary Industry
Biotechnology
About
Established in 2019 and based in California, US, AusperBio Therapeutics Inc. operates as a biopharmaceutical developer that focuses on intrahepatic and extrahepatic targeted therapy. The company has acquired Med-Oligo ASO independent intellectual property rights. The leaders are doctors and some of them are from the US.
In September 2025, AusperBio raised USD 63 million in series B2 funding led by returning investor Qiming Venture Partners with participation from returning investors CDH Investments, Genesis Capital, Hankang Capital, Sherpa Healthcare Partners, YuanBio Venture. The company develops Med Oligo ™ small nucleic acid drug platform, hepatitis B therapeutic vaccine platform and nasal spray antibody platform. Its R&D drug includes AHB-137 which is a naked antisense oligonucleotide (ASO). And AHB-137 can treat and prevent chronic hepatitis B and other infectious diseases.
The company will used the September 2025 funding to accelerate the clinical trial progress, proactively plan the commercialization and industrialization of AHB-137 and continue to expand the company's innovative pipeline R&D.
Current Investors
InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.ausperbio.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.